Latest News Articles

Everyone can read the (free) Standard Edition articles. However,  the Plus Edition articles are accessible only to (paid) Plus Edition subscribers. 

Read the (+) Plus Edition articles (a Plus Edition username and password is required).

Please limit your comments about the information in the article. If you would like to start a new message, perhaps about a different topic, you are invited to use the Discussion Forum for that purpose.

Do you have comments, questions, corrections or additional information to any of these articles? Before posting your words, you must first sign up for a (FREE) Standard Edition subscription or a (paid) Plus Edition subscription at: https://eogn.com/page-18077.

If you do not see a Plus Sign that is labeled "Add comment," you will need to upgrade to either a (FREE) Standard Edition or a (paid) Plus Edition subscription at: https://eogn.com/page-18077.

Click here to upgrade to a Plus Edition subscription.

Click here to find the Latest Plus Edition articles(A Plus Edition user name and password is required to view these Plus Edition articles.)

Do you have an RSS newsreader? You may prefer to use this newsletter's RSS feed at: https://www.eogn.com/page-18080/rss and then you will need to copy-and-paste that address into your favorite RSS newsreader.

New! Want to receive daily email messages containing the recently-added article links, complete with “clickable addresses” that take you directly to the article(s) of interest?

Best of all, this service is available FREE of charge. (The email messages do contain advertising.) If you later change your mind, you can unsubscribe within seconds at any time. As always, YOU remain in charge of what is sent to your email inbox. 

Information may be found at: https://eogn.com/page-18080/13338441 with further details available at: https://eogn.com/page-18080/13344724.





Latest Standard Edition Articles

  • 16 Feb 2022 6:32 PM | Anonymous

    NOTE: This article is off-topic. That is, it does not concern anything to do with genealogy, DNA, or related topics normally found in this newsletter. However, I suspect that many newsletter readers will be interested in this article for many different purposes:

    I have written often about the numerous advantages of Chromebooks. I own two Chromebooks and love 'em both. One Chromebook has become my primary traveling computer, even though I already own an expensive and much more powerful Macintosh laptop. In short, I prefer to risk the low-cost laptop when exposing it to travel damage and theft. Besides, the Chromebook does everything I need to accomplish when traveling.

    Now Google has announced a future product that will convert older, lower-powered Windows and Macintosh computers into Chromebooks. If you have an older computer in the closet that you are not using any more, this might be a great zero-cost project for you to use, either for yourself or for a family member (either an adolescent or adult) who does not yet have their own computer.

    Google today announced early access to Chrome OS Flex, which makes the Chrome OS operating system found on Chromebooks downloadable onto a Mac or Windows PC.

    Chrome OS Flex allows individuals, schools, or businesses to download Chrome OS onto a USB drive for free and install it onto their Mac or Windows PC. The OS could also be booted from a USB drive instead of installed or launched via network deployment by an IT department.

    Google is positioning Chrome OS Flex as an answer to old Mac and Windows PCs that might not be able to handle the latest version of their native OS and/or that might not be owned by folks with budgets to replace the devices. Rather than buying new hardware, consumers or IT departments could install the latest version of Chrome OS Flex.

    Google's Chrome OS Flex is currently available as early access in the dev channel with bugs expected. You can read more at: https://bit.ly/3HWzbXn.


  • 16 Feb 2022 12:19 PM | Anonymous

    If you are researching Black ancestry in Nashville, you will be interested in a new spreadsheet listing more than 14,000 rows of data, which might bore you – until the names stop you cold: Eliza, age 3; Peter, 11; Martha Foster, 1. After each, it reads “child of Albert and Betsy.”

    On Nov. 1, 1852, it says, John Nichol sold Albert and Betsy, along with Eliza, Peter, Martha Foster and their other five children to Bradford Franklin. Davidson County legally recorded this enslaved family as property, bought and sold.

    Metro Archivist Ken Fieth has spent some 25 years compiling a searchable spreadshee. Transaction by transaction, it lists buyer, seller, enslaved person’s name, gender, age and relatives (if known).

    These transactions are part of what made us who we are, what made Nashville the place that it is. It is the big “how” and the big “why” of the racism that still plagues us.

    You can read more in an article by Karen Johnson and Learotha Williams, published by the Tennessean, at https://bit.ly/3I2CE6U.

    The spreadsheet may be found at: https://data.nashville.gov/Genealogy/Nashville-Slave-and-Free-People-of-Color-Database/fqu3-hv5z.


  • 15 Feb 2022 8:27 AM | Anonymous

    Jackson State is one of the inaugural recipients of Getty Images grants to help historically Black colleges and universities digitize their photo archives to preserve the photos and help document Black history at the universities. "The goal is that everybody knows what we have," Locord Wilson, Jackson State University interim dean of libraries, said Thursday, Feb. 3, 2022. "It's a hidden treasure."

    You can read more and view a number of pictures at: https://bit.ly/3gOn6ra.


  • 15 Feb 2022 8:18 AM | Anonymous

    The Dodge/Jefferson Counties Genealogical Society’s library at 504 S. Fourth St., Watertown, Wisconsin, is temporarily closed as the society installs improved shelving and rearranges its materials.

    The society hopes to reopen the library two or three weeks from now. Status updates on the library’s reopening will be posted on the society’s Facebook page, https://www.facebook.com/dodgejeffgensoc.org/.

    During this transitional time, there may also be a delay in online orders for obituaries and in answers to lookup requests. As always, questions about the library or about genealogical concerns can be directed to dodgejeffersongensoc@gmail.com.


  • 14 Feb 2022 2:04 PM | Anonymous

    The following announcement was written by MyHeritage:

    Love is in the air! Celebrate Valentine’s Day by diving into the love stories in your family history with this special offer: all marriage records will be free to access from February 13–20, 2022.

    Search free marriage records on MyHeritage 

    Marriage records provide a fascinating glimpse into the moments when new families are born. They usually contain the names, birth dates, birthplaces, and places of residence of the bride and groom, and sometimes contain information on the parents of the bride and groom or witnesses, who may have been family friends or other relatives. MyHeritage is home to 164 marriage record collections containing almost 600 million records from all over the world, some of which include beautifully scanned images, and some of which are exclusive to MyHeritage.

    Since last Valentine’s Day, we’ve added some essential and intriguing collections — for example, France, Church Marriages and Civil Marriages and Brazil, Pernambuco Marriages, 1800–1960.

    Normally, a Complete or Data plan is required to view these records, but for 8 days only, you’ll be able to search and view them for free.

    What are you waiting for? Go ahead and get searching! We can’t wait to hear what you find.

    Search free marriage records on MyHeritage

  • 14 Feb 2022 8:52 AM | Anonymous

    I have no idea if this is a valuable product or if it is based on a fallacy. However, the announcement is interesting, to say the least. The following is an excerpt from a (sponsored article) at: https://nypost.com/2022/02/11/rootine-uses-your-dna-to-build-a-personalized-multivitamin/:

    "Rootine understands the multi-nutrient is only effective when it’s addressing what that specific user needs. That’s why the company devised a process to create bespoke nutrient supplements engineered for each individual user, augmenting natural vitamins and minerals their unique body needs to best optimize their health.

    "Unlike other services offering customized supplements, Rootine goes even deeper, using lifestyle factors in conjunction with DNA, blood levels, and even artificial intelligence to create a personalized daily multi-nutrient formula that best addresses each person’s distinctive biology.

    "After taking Rootine’s short lifestyle assessment covering your health goals, current lifestyle choices, and more, its process devised by expert geneticists and supplement technicians gets even more granular. Users submit a DNA sample for testing or even their own blood to help get the most precisely accurate picture of their particular metabolism.

    "For users who recently did bloodwork through their doctor or received DNA results from a service like Ancestry.com, those results can be submitted straight to Rootine, saving customers the cost of those added tests."

    You can read the article at: https://nypost.com/2022/02/11/rootine-uses-your-dna-to-build-a-personalized-multivitamin/.


  • 11 Feb 2022 5:18 PM | Anonymous

    The following is a Plus Edition article written by and copyright by Dick Eastman.

    Warning: This article contains personal opinions.

    As you might expect with any conference of 150 or more presentations, there are many stories to be told at most any major genealogy conference. One that I hear often concerns the high failure rate of hardware and software among the presenters. At some national conferences, I have heard stories of no less five or six different presenters who experienced major problems with their laptop computers, operating system, projectors, PowerPoint slides, or other critical computer tools.

    Some of the problems happen at the very last moment as the presenters are setting up at the podium to begin their talks.

    The remainder of this article is reserved for Plus Edition subscribers only. If you have a Plus Edition subscription, you may read the full article at: https://eogn.com/(*)-Plus-Edition-News-Articles/12593392.

    If you are not yet a Plus Edition subscriber, you can learn more about such subscriptions and even upgrade to a Plus Edition subscription immediately at https://eogn.com/page-18077.


  • 11 Feb 2022 1:31 PM | Anonymous

    From the Massachusetts Registry of Vital Records and Statistics' web site:

    Due to severe flooding at the offices of the Registry of Vital Records and Statistics (RVRS), all public counter service is expected to be closed at least through 2/21/2022. RVRS is working diligently to restore access to records and equipment as quickly as possible.

    Birth, marriage, and death records can be obtained at local City and Town Clerk offices. For births and deaths, you may obtain records at the city/town of event or the residence town at the time of event. For marriages, you may obtain records at the city/town where intentions (application) were filed. A link to city and town offices can be found here: https://www.mass.gov/lists/massachusetts-city-and-town-websites.

    A subset of birth and death records are still accessible for issuance from RVRS. No marriage records are currently accessible for issuance. Customers can order certified copies of accessible birth and death records from RVRS online or by mail, but there will likely be delays in fulfillment. No overnight orders can be accommodated at this time.  Please expect a 3-week turnaround for online orders and a 5-week turnaround for mail orders. Records currently available for issuance are:

    • Birth records for years 1953 – present.
    • Death records for years 1977 – present.

    Updates will be posted as more information becomes available. Please email vital.recordsrequest@mass.gov if you have any questions.


  • 11 Feb 2022 1:22 PM | Anonymous

    The following announcement was written by TheGenealogist:

    TheGenealogist’s latest release of transcripts of RAF ORBs provide the most complete collection of indexed AIR 27 records

    TheGenealogist has today released over 4.2 million transcripts for its RAF Operations Record Books (ORBs), fully searchable by Name, Rank, Aircraft, Squadron, and Date plus many other fields, making it simpler to find your air force ancestors.

    TheGenealogist uniquely allows you to search the period 1911-1963. With over 11 million records online, this is the largest collection of searchable AIR 27 records making it the best place to find details about your RAF ancestors.

    Handley Page Hampdens taking off in formation at RAF Waddington

    TheGenealogist’s significant transcription effort has been aimed at providing detailed indexes which cover 1911 to 1963.

    Mark Bayley, Head of Content at TheGenealogist said: “We are delighted to be releasing such a large number of AIR 27 ORBs, making TheGenealogist the most comprehensive site for AIR 27 records online.”

    The ORBs on TheGenealogist include not only the journal-like day to day entries recorded on Form 540 in which you can find RAF personnel mentioned, but also all of the appendices that go along with these documents, giving many statistical details as well as “Secret Orders”.

    Some feedback TheGenealogist has received:

    One of your best. To be able to follow the day to day activities of individuals down to the hours the planes take off and land is amazing. I look forward to the rest of this data set.”

    A 2 minute search brought up 2 years of operations logs for my Father, who was a pilot in 123 Squadron stationed in North Africa, India & Burma. They are full of amazing information. Everything from a near miss when a Japanese machine gun bullet ‘entered his cockpit’, what films they watched & complaints about the food. Just wonderful.”

    Just to say a big THANK YOU for giving my family access to records of my late Uncle Douglas Thom's operations in 90 Squadron Bomber Command in 1944. We have been very frustrated that his log books seem to have "disappeared" when his home in mid Wales was cleared. Now at least we have a time-line of his sorties and more information to add to his "not often spoken about" story. I will be passing what you have on him to my cousin, his son Doug, in Canada.”

    Learn more about RAF records and read TheGenealogist’s free articles here: https://www.thegenealogist.co.uk/raf/

    This collection is provided in association with The National Archives.

    These records and many more are available to Diamond subscribers of TheGenealogist.co.uk

    About TheGenealogist

    TheGenealogist is an award-winning online family history website, who put a wealth of information at the fingertips of family historians. Their approach is to bring hard to use physical records to life online with easy to use interfaces such as their Tithe and newly released Lloyd George Domesday collections.

    TheGenealogist’s innovative SmartSearch technology links records together to help you find your ancestors more easily. TheGenealogist is one of the leading providers of online family history records. Along with the standard Birth, Marriage, Death and Census records, they also have significant collections of Parish and Nonconformist records, PCC Will Records, Irish Records, Military records, Occupations, Newspaper record collections amongst many others.

    TheGenealogist uses the latest technology to help you bring your family history to life. Use TheGenealogist to find your ancestors today!

  • 11 Feb 2022 10:08 AM | Anonymous

    The following was written by 23andMe:

    • Third quarter revenue of $57 million
    • Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials
    • Vision of genetics-based primary care offers potential for millions of people to live healthier lives

    SUNNYVALE, Calif., Feb. 10, 2022 -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (“Q3”) of its fiscal year 2022 (“FY2022”), which ended December 31, 2021. 23andMe is the only company with multiple FDA authorizations for over-the-counter genetic health risk reports, and in particular the only company FDA authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The company has also created the world’s largest crowdsourced platform for genetic research, which it is using to pursue drug discovery programs rooted in human genetics across a spectrum of disease areas.

    “We’ve made significant progress on both our consumer business and therapeutics efforts these last few months. On the consumer side, we acquired Lemonaid Health, which brings telehealth services that offer online access to healthcare professionals with e-prescribing, pharmacy and testing services to patients in all 50 states, the District of Columbia, and the United Kingdom. Combined with our Personal Genome Service, this positions us to achieve our vision of personalized, genetics-based primary care at scale. We also received FDA clearance for a direct-to-consumer genetic test on a hereditary prostate cancer marker, further expanding our ability to provide individuals with direct access to impactful health information that can help them make important life decisions,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “On the therapeutics side, we launched our first wholly-owned therapeutic, 23ME’610, into a Phase 1 clinical trial. This is our second immuno-oncology drug to enter clinical trials, following GSK’608, and marks an important milestone in our goal to find new medicines for people with serious unmet medical needs. We look forward to continuing to advance our pipeline of more than 40 programs across a range of disease areas, addressing targets that we have validated using human genetics.”

    Recent Highlights

      • Initiated Phase 1 clinical trial for first wholly owned immuno-oncology antibody, 23ME’610, targeting CD200R1

      • Announced that GSK, our key collaborator in therapeutics, elected to extend the exclusive target discovery period under the collaboration agreement for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database. 23andMe will receive a one-time payment of $50 million

      • Elected for a royalty option on GSK’608, the joint collaboration program with GSK targeting CD96. 23andMe will be eligible to earn tiered worldwide royalties up to the low double digits if GSK’608 is successfully commercialized.

      • Expanded customer database to 12.2 million genotyped customers

      • Received FDA clearance for direct-to-consumer genetic test on a hereditary prostate cancer marker

      • Launched two new reports for customers subscribed to 23andMe+, a membership service that offers insights and features to give members even more actionable information to live healthier lives. These new reports use machine learning to create a statistical model that estimates a person’s likelihood of developing a specific condition using thousands of genetic markers, along with a person’s ethnicity and birth sex. The new reports released in the third quarter were:

        • Nearsightedness (myopia) report

        • Severe acne report

      • Added new ancestry analysis, including additional insights into some customers’ indigenous genetic ancestry from North America and ancestral connections to 25 African ethnolinguistic groups

      • Received recognition from Inc. magazine as one of the “Best-Led Companies of 2021”; from Comparably, which listed Anne Wojcicki as one of the top CEOs among large companies and from Fast Company, which listed 23andMe as one of the “Brands that Matter”

      • Completed the redemption of all outstanding warrants in December 2021

    “We are working to integrate Lemonaid Health’s telehealth services and our personal genetics services with the goal of bringing a genetics-based primary care service to our customers. This unique offering would enable our medical professionals to take a prevention-based, genetically-informed approach with our customers to help them live healthier lives. Beginning this quarter, Lemonaid Health’s financial results are incorporated into our consolidated results,” said Steve Schoch, Chief Financial Officer of 23andMe. “On the Therapeutics side, we were also pleased with GSK’s election to renew for a fifth year, with its $50 million fee. This further validates the value of our database to genetically validate targets for drug development and the potential for this approach to increase the probability of success in bringing new therapies to patients.”

    FY2022 Third Quarter Financial Results
    Total revenue for the three and nine months ended December 31, 2021, was $57 million and $171 million, respectively, representing increases of 3% and 10%, respectively, for the same periods in the prior year. Third quarter revenue growth was primarily due to the addition of two months of Telehealth business revenue from the recent acquisition of Lemonaid Health and higher subscription revenue. These increases were partially offset by lower Personal Genome Service (“PGS”) revenue primarily due to the shift in a promotional channel partner’s event, which occurred in the second quarter of FY2022 as compared to the third quarter of FY2021. Nine-month revenue growth was primarily driven by higher PGS revenue, subscription revenue and the addition of two months of revenue from the Telehealth business.

    Consumer services revenue represented approximately 81% of total revenue for the three and nine months ended December 31, 2021, and research services revenue, substantially all derived from the collaboration with GSK, accounted for approximately 19% of total revenue.

    Operating expenses for the three and nine months ended December 31, 2021 were $124 million and $271 million, respectively, compared to $71 million and $191 million for the same periods in the prior year. The increase in operating expenses was primarily attributable to increased sales and marketing expenses, consistent with the seasonal promotion activities of the PGS business, therapeutics-related research and development expenses, one-time transaction costs associated with the acquisition of Lemonaid Health and incorporation of Telehealth operating expenses.

    Net loss for the three and nine months ended December 31, 2021 was $89 million and $148 million, respectively, compared to net losses of $45 million and $117 million for the same periods in the prior year. The increase in net loss for the nine-month period ended December 31, 2021 was primarily driven by higher operating expenses (as noted above) offset by changes in fair value of warrant liabilities of $33 million. In December 2021, the company redeemed all outstanding warrants.

    Total Adjusted EBITDA (as defined below) for the three and nine months ended December 31, 2021 was $(64) million and $(121) million, respectively, compared to $(25) million and $(65) million for the same periods in the prior year. The decrease in total Adjusted EBITDA was driven primarily by the increase in operating expenses listed above, excluding one-time transaction costs. Adjusted EBITDA for the three and nine months ended December 31, 2021 for the Consumer & Research Services segment was $(32) million and $(33) million, respectively, compared to $(2) million and $(5) million for the same periods in the prior year. The decrease in this segment was driven primarily by the increase in operating expenses listed above, excluding therapeutics-related research and development expenses and one-time transaction costs.

    Balance Sheet
    23andMe ended Q2 FY2022 with cash of $586 million, compared to $282 million as of March 31, 2021. The increase was attributable to the $560 million in gross proceeds from the completion of the business combination with the Virgin Group Acquisition Corp during the first quarter of FY2022. In Q3 FY2022, 23andMe paid approximately $102 million in cash consideration for the acquisition of Lemonaid Health, of which approximately $13 million was placed in escrow to cover a potential purchase price adjustment and to secure the indemnification obligations of the former equity holders of Lemonaid Health.

    FY2022 Financial Guidance
    23andMe is updating its FY2022 guidance following the inclusion of telehealth operations into its consumer business and the redemption of all outstanding warrants. The projected range for full year revenue for fiscal 2022, which will end on March 31, 2022, has been increased from $250 to $260 million to $268 to $278 million. The increase in projected revenue is primarily due to the addition of telehealth services to 23andMe’s consumer business. The projected range for full year net loss has decreased from $210 to $225 million to $205 to $220 million. The decrease in projected net loss is primarily due to the favorable effect of the warrant fair value adjustment following warrant redemption offset by the inclusion of telehealth operating expenses, integration and merger-related transaction costs. The projected range for full year adjusted EBITDA loss has increased from $143 to $158 million to $148 to $163 million as we expect telehealth net losses to be partially offset by other beneficial effects in our operations.

    Conference Call Webcast Information
    23andMe will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 10, 2022 to discuss the financial results for Q3 FY2022 and report on business progress. The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be available at the same address for a limited time within 24 hours after the event.

    About 23andMe
    23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with approximately 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject to other risks and uncertainties that are described in 23andMe’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed with the Securities and Exchange Commission (“SEC”) on November 10, 2021 and in the reports subsequently filed by 23andMe with the SEC. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

    Use of Non-GAAP Financial Measure

    To supplement the 23andMe’s unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that 23andMe defines as net income before net interest expense (income), net other expense (income), changes in fair value of warrant liabilities, income tax benefit, depreciation and amortization of fixed assets, amortization of internal use software, amortization of acquired intangible assets, non-cash stock-based compensation expense, acquisition-related costs, and expenses related to restructuring and other charges, if applicable for the period. 23andMe has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

    Adjusted EBITDA is a key measure used by 23andMe’s management and the board of directors to understand and evaluate operating performance and trends, to prepare and approve 23andMe’s annual budget and to develop short- and long-term operating plans. 23andMe provides Adjusted EBITDA because 23andMe believes it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods. Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23andMe’s core operating performance. In particular, 23andMe believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of 23andMe’s business. Accordingly, 23andMe believes that Adjusted EBITDA provides useful information in understanding and evaluating operating results in the same manner as 23andMe’s management and board of directors.

    In evaluating Adjusted EBITDA, you should be aware that in the future 23andMe will incur expenses similar to the adjustments in this presentation. 23andMe’s presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. When evaluating 23andMe’s performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results.

Eastman's Online Genealogy Newsletter









































Powered by Wild Apricot Membership Software